We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Screening Tests Detect Cystic Fibrosis Gene Mutations

By LabMedica International staff writers
Posted on 22 Jul 2009
Two cystic fibrosis (CF) kits can quickly and accurately detect up to 39 of the most common cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations from a child or parent's blood sample, or bloodspot. More...
They provide assistance in CF screening of newborns, confirmatory diagnostic testing in newborns and children, and can be used for carrier testing in adults of reproductive age.

The kits are known as the xTAG Cystic Fibrosis 39 Kit v2 and xTAG Cystic Fibrosis 71 Kit v2. The latter screens for all of the genetic mutations in the xTAG Cystic Fibrosis 39 Kit v2 plus an additional 32 mutations typically found in specific populations. To date, more than 1,500 disease-causing CFTR mutations have been identified.

The xTAG tests are designed to be fast and easy for use, requiring only about one hour of hands-on time to process 48 purified samples. They enable physicians to select the CFTR gene mutations for which they want to test. Additionally, reflex tests are incorporated in these kits. All results are available for analysis at each run. With validated performance criteria, the xTAG Cystic Fibrosis 39 Kit v2 and xTAG Cystic Fibrosis 71 Kit v2 are accurate and reproducible.

Luminex Corp. (Austin, TX, USA), a company dealing in multiplexed solutions, announced that it has launched the two new CF tests in Europe as CE marked in vitro diagnostic (IVD) products. Milan Macek, professor of medical and molecular genetics, division of clinical molecular genetics and the national cystic fibrosis center at University Hospital Motol and Second School of Medicine Charles University (Prague, Czech Republic), explained, "The geographic distribution of CFTR gene mutations differs significantly among the European populations. Some are ubiquitous, some are rare, and some are population-specific. The possibility of having a test that can cover a wide range of mutations found in different ethnic groups is very important and will allow doctors to have better confidence [in] CF diagnosis, especially when we have cases where the ethnicity of the patient is difficult to assess."

Cystic fibrosis causes the body to produce thick mucus that can clog the lungs and affect the digestive system. The chronic disease is inherited when both of a child's parents carry the CFTR gene mutation that causes CF. Approximately 36,000 Europeans have cystic fibrosis and each year 2,500 children with the disease are born. Although CF is most common among western European populations, it can affect people of any race. According to European Cystic Fibrosis Society, as many as one in 30 Europeans are carriers of a CF-causing gene mutation.

Information about the new xTAG tests was presented at the 2009 European Cystic Fibrosis Conference, which was held June 10-13, 2009 in Brest, France.

Related Links:
Luminex Corp.
University Hospital Motol and Second School of Medicine Charles University



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Multilevel Whole Blood Calibrator Set
6PLUS1
New
Varicella Zoster Test
ZEUS ELISA Varicella Zoster IgG Test System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: T cell immunity could be a marker for early Parkinson’s treatment (Photo courtesy of Shutterstock)

T Cells in Blood Can Detect Parkinson's Years Before Diagnosis

Diagnosing Parkinson’s disease before the appearance of motor symptoms remains one of neurology’s most significant challenges. Patients can go years—even decades—without a diagnosis, as subtle early indicators... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.